Syros Pharmaceuticals reports Q3 EPS (16c), consensus (72c)

Syros did not recognize revenue in the third quarter, as compared to $3.8M for the third quarter of 2023. The decrease reflects the termination of Syros’ collaboration agreement with Pfizer. “It is a very exciting time at Syros, as we approach a significant milestone in our efforts to establish tamibarotene as a potential new standard of care for higher-risk myelodysplastic syndrome (HR-MDS) patients with RARA gene overexpression. We expect to announce topline results from the pivotal SELECT-MDS-1 Phase 3 trial in mid-November, and if successful, we plan to file our first New Drug Application (NDA) and to launch tamibarotene in the U.S.,” said Conley Chee, CEO of Syros.